Here at The Center for Hormone Therapy, we know first-hand how estradiol therapy can offer great benefits to women as they age. Menopause begins a new chapter in a woman’s health, marked by a lasting decline in ovarian estrogen production. Estradiol, the main estrogen produced during the reproductive years, influences much more than menstrual cycles. Its decline affects bone turnover, vaginal tissues, temperature regulation, and blood vessels. For postmenopausal women, estradiol therapy can relieve bothersome symptoms and help preserve bone and cardiovascular health. Research also suggests that starting treatment closer to menopause may produce more favorable vascular effects than starting many years later.
Supporting Stronger Bones
Bone is living tissue that continually breaks down and rebuilds. After menopause, lower estrogen levels accelerate bone breakdown, allowing bone loss to outpace formation. Over time, declining bone mineral density can increase vulnerability to osteoporosis and fractures. Systemic estrogen therapy slows this process and helps preserve bone density. Its ability to prevent bone loss and reduce fracture risk is among its best-established benefits.
The Danish Osteoporosis Prevention Study, commonly called DOPS, provides evidence supporting these skeletal benefits. In a five-year analysis of a subgroup of participants, women receiving hormone therapy had improved bone mineral density compared with untreated women, alongside reductions in markers of bone turnover. These findings support estradiol-based treatment’s ability to protect the skeleton after the menopausal transition.
EPAT: Evidence of Slower Arterial Changes
The Estrogen in the Prevention of Atherosclerosis Trial, or EPAT, studied oral estradiol in healthy postmenopausal women without established cardiovascular disease. Participants received 1 mg of oral estradiol daily or placebo for two years. Researchers measured carotid intima-media thickness, an ultrasound measure of arterial wall thickness used to track subclinical atherosclerosis.
Women assigned estradiol experienced slower progression of carotid wall thickening overall. The benefit was seen among women who were not taking lipid-lowering medications such as statins; no significant additional effect appeared among those receiving those medications. EPAT supports a potentially favorable effect on early arterial disease.
Why Starting Within Six Years Matters
The specific finding about beginning oral estradiol within six years of menopause comes from the Early versus Late Intervention Trial with Estradiol, or ELITE.
ELITE enrolled 643 healthy postmenopausal women and compared oral estradiol with placebo. Among participants who started treatment less than six years after menopause, carotid artery wall thickness increased more slowly with estradiol: approximately 0.0044 millimeters annually, compared with 0.0078 millimeters with placebo. This benefit was not observed in women starting treatment ten or more years after menopause.
Cardiovascular Findings From the Danish Study
DOPS also examined clinical cardiovascular outcomes. Its randomized component included 1,006 generally healthy women who began treatment near menopause. Women with a uterus generally received estradiol plus synthetic progestin; women who had undergone hysterectomy received estradiol alone.
After ten years of estradiol therapy and an additional 6 years of follow up, there remained a significant improvement in the rates of heart attacks, heart failure, and mortality in the group randomized to therapy.
Choosing Therapy for Your Health
Estradiol also effectively treats hot flashes, night sweats, brain fog, and can relieve menopausal vaginal and urinary symptoms.
At The Center for Hormone Therapy by Skinology, a consultation offers an opportunity to discuss symptoms, bone health, cardiovascular risk factors, and treatment preferences. The goal is a carefully selected plan that supports comfort, function, and long-term health while balancing the benefits and risks of therapy.